17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Secondary immune thrombocytopenia (ITP) as an initial presentation of Whipple’s disease

      case-report

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Immune thrombocytopenia (ITP) is a heterogeneous autoimmune disease characterized by low platelet count that has been associated with a number of chronic infections but rarely described as a manifestation of Whipple’s disease (WD). We present a case of Whipple’s disease in a patient initially diagnosed with ITP.

          A 46-year old male in the fifth decade of life presented with presumed idiopathic ITP and was treated with several therapies including corticosteroids, rituximab, and thrombopoietin receptor agonists. Several years later, he developed weight loss and worsening arthralgias. He was found to have evidence of WD in a jejunal lymph node, the duodenum, and the cerebral spinal fluid (CSF). His diagnosis of WD, as a cause of secondary ITP, came a full 8 years after he was discovered to have thrombocytopenia and over 4 years after he was diagnosed with ITP.

          WD is an uncommon, multiorgan system disease caused by the actinomycete Tropheryma whipplei. Whipple’s disease presents a diagnostic challenge due to the wide array of possible presenting clinical manifestations, as well as a prolonged time course with separation of symptoms over many years. While T. whipplei is ubiquitous in the environment, few individuals develop clinical disease, raising the prospect that select immunodeficiencies, both singular or in combination, may play a role in infection.

          While rare, in the appropriate clinical setting, one should consider infection with T. whipplei in addition to other chronic infections as a cause of secondary ITP regardless of how long ago the diagnosis of ITP was made.

          Related collections

          Most cited references13

          • Record: found
          • Abstract: found
          • Article: not found

          The ITP syndrome: pathogenic and clinical diversity.

          Immune thrombocytopenia (ITP) is mediated by platelet autoantibodies that accelerate platelet destruction and inhibit their production. Most cases are considered idiopathic, whereas others are secondary to coexisting conditions. Insights from secondary forms suggest that the proclivity to develop platelet-reactive antibodies arises through diverse mechanisms. Variability in natural history and response to therapy suggests that primary ITP is also heterogeneous. Certain cases may be secondary to persistent, sometimes inapparent, infections, accompanied by coexisting antibodies that influence outcome. Alternatively, underlying immune deficiencies may emerge. In addition, environmental and genetic factors may impact platelet turnover, propensity to bleed, and response to ITP-directed therapy. We review the pathophysiology of several common secondary forms of ITP. We suggest that primary ITP is also best thought of as an autoimmune syndrome. Better understanding of pathogenesis and tolerance checkpoint defects leading to autoantibody formation may facilitate patient-specific approaches to diagnosis and management.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP)

            Immune thrombocytopenia (ITP) is a complex autoimmune disease characterized by low platelet counts. The pathogenesis of ITP remains unclear although both antibody-mediated and/or T cell-mediated platelet destruction are key processes. In addition, impairment of T cells, cytokine imbalances, and the contribution of the bone marrow niche have now been recognized to be important. Treatment strategies are aimed at the restoration of platelet counts compatible with adequate hemostasis rather than achieving physiological platelet counts. The first line treatments focus on the inhibition of autoantibody production and platelet degradation, whereas second-line treatments include immunosuppressive drugs, such as Rituximab, and splenectomy. Finally, third-line treatments aim to stimulate platelet production by megakaryocytes. This review discusses the pathophysiology of ITP and how the different treatment modalities affect the pathogenic mechanisms.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Whipple's disease: new aspects of pathogenesis and treatment.

              100 years after its first description by George H Whipple, the diagnosis and treatment of Whipple's disease is still a subject of controversy. Whipple's disease is a chronic multisystemic disease. The infection is very rare, although the causative bacterium, Tropheryma whipplei, is ubiquitously present in the environment. We review the epidemiology of Whipple's disease and the recent progress made in the understanding of its pathogenesis and the biology of its agent. The clinical features of Whipple's disease are non-specific and sensitive diagnostic methods such as PCR with sequencing of the amplification products and immunohistochemistry to detect T whipplei are still not widely distributed. The best course of treatment is not completely defined, especially in relapsing disease, neurological manifestations, and in cases of immunoreconstitution after initiation of antibiotic treatment. Patients without the classic symptoms of gastrointestinal disease might be misdiagnosed or insufficiently treated, resulting in a potentially fatal outcome or irreversible neurological damage. Thus, we suggest procedures for the improvement of diagnosis and an optimum therapeutic strategy.
                Bookmark

                Author and article information

                Contributors
                Journal
                IDCases
                IDCases
                IDCases
                Elsevier
                2214-2509
                28 June 2017
                2018
                28 June 2017
                : 12
                : e4-e6
                Affiliations
                [a ]Novant Health Infectious Disease Specialists, 1381 Westgate Center Drive, Winston-Salem, NC 27103, USA
                [b ]Novant Health Oncology Specialists, 3333 Silas Creek Parkway, Winston-Salem, NC 27103, USA
                [c ]Novant Health Salem Surgical Associates, 2915 Lyndhurst Avenue, Winston-Salem, NC 27103, USA
                [d ]Pathologists Diagnostic Services, 3333 Silas Creek Parkway, Winston-Salem, NC 27103, USA
                [e ]Gastroenterology Associates of the Piedmont, 1901 South Hawthorne Road #310, Winston-Salem, NC 27103, USA
                Author notes
                [* ]Corresponding author. dhpriest@ 123456novanthealth.org
                Article
                S2214-2509(17)30083-5
                10.1016/j.idcr.2017.05.010
                6010930
                b9916b92-cd1c-45b5-8701-edfd50fa24b0
                © 2017 The Authors

                This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                : 8 May 2017
                : 12 May 2017
                Categories
                Article

                whipple’s,thrombocytopenia,itp
                whipple’s, thrombocytopenia, itp

                Comments

                Comment on this article